使研究人员，临床医生和公众可以访问所有临床试验的结果不仅促进了临床研究的透明度，而且还确保所有证据都可用于知情的临床决策。对研究更大的研究的广泛支持也许最好证明Alltrials倡议.

However, actually getting all the results published is quite another thing and it’s with this goal in mind that Peter Doshi and his colleagues proposed their initiativeRestoring Invisible and Abandoned Trials (RIAT)在《英国医学杂志》中。从他们的出版物开始的六个月，试验和the生物医学的负面结果杂志have written an open letter (which we’ve reproduced below) to almost 200 publication managers in large pharmaceutical companies to follow up on the 12-month ‘grace period’ proposed in the RIAT publication.

亲爱的同事，

In June, Doshi and colleagues published their article‘Restoring invisible and abandoned trials (RIAT): a call for people to publish the findings’在BMJ,邀请独立的恢复身份验证ors’ to step in and take charge of unpublished or misrepresented trials. This article presented not so much a ‘publish or be damned’ approach as a ‘publish or be published’ one; however, the proposal gave the original triallists and sponsors a one-year grace period to publish the work themselves.

We are writing to declare生物中央``致力于支持和促进所有试验结果的发布，以完成科学记录，并鼓励原始的试验员和赞助商公开陈述他们的意图，以发表其结果并遵循这种意图。太多的期刊不接受不完整或负面的结果，因此，作为BMC医学证据投资组合的旗舰标题的主持人试验和its sister journal the生物医学的负面结果杂志，我们邀请RIAT作者向我们提交他们的“恢复”审判报告以供我们出版，因为我们认为所有有充分的道德生物医学研究，无论结果如何。

这些论文将在我们现有的背景下考虑publication criteria和, as with any other study, a RIAT study will undergo review by an Associate Editor and external peer reviewers. However, negative or controversial results, or indeed unfinished studies, are no barrier to publication and we provide a simplified format for the reporting of this information, to facilitate publication and ensure that the published record is complete.

We are committed to making the results of all clinical trials accessible to researchers, clinicians and the public, to promote transparency and to make the best evidence available for informed clinical decision making. While we appreciate the difficulties presented by analysing, authoring, peer-reviewing and publishing the trials, if we do not make the effort we will not achieve progress toward the ultimate goal of transparency of clinical trials and access to all available data for making the best clinical decisions. Therefore, we want to appeal to triallists to make this effort to set the scientific record straight. Thank you.

Yours sincerely,

Doug Altman, Curt Furberg, Jeremy Grimshaw and Bjorn Olsen